A preclinical study has shown that tumors infected with a replication-defective adenovirus carrying the TNF-α gene under control of the Egr1 promoter could respond to radiotherapy with local production of TNF-α and substantial increases in anti-tumor activity, without toxicities encountered when this cytokine was administrated systemically [29]. The gene discussed is EGR1; the disease is neoplasm.